STAAR Surgical Co
NASDAQ:STAA

Watchlist Manager
STAAR Surgical Co Logo
STAAR Surgical Co
NASDAQ:STAA
Watchlist
Price: 23.12 USD -3.18%
Market Cap: 1.1B USD
Have any thoughts about
STAAR Surgical Co?
Write Note

STAAR Surgical Co
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

STAAR Surgical Co
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
STAAR Surgical Co
NASDAQ:STAA
Other Long-Term Assets
$19.1m
CAGR 3-Years
65%
CAGR 5-Years
54%
CAGR 10-Years
32%
Haemonetics Corp
NYSE:HAE
Other Long-Term Assets
$164.8m
CAGR 3-Years
31%
CAGR 5-Years
37%
CAGR 10-Years
30%
ICU Medical Inc
NASDAQ:ICUI
Other Long-Term Assets
$121.3m
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
36%
Align Technology Inc
NASDAQ:ALGN
Other Long-Term Assets
$1.8B
CAGR 3-Years
4%
CAGR 5-Years
77%
CAGR 10-Years
52%
Lantheus Holdings Inc
NASDAQ:LNTH
Other Long-Term Assets
$151.5m
CAGR 3-Years
14%
CAGR 5-Years
7%
CAGR 10-Years
18%
Merit Medical Systems Inc
NASDAQ:MMSI
Other Long-Term Assets
$69.6m
CAGR 3-Years
15%
CAGR 5-Years
2%
CAGR 10-Years
15%
No Stocks Found

STAAR Surgical Co
Glance View

Market Cap
1.1B USD
Industry
Health Care

In the early throes of medical innovation, STAAR Surgical Co. carved a niche within the ophthalmic industry, where its focus on implantable lenses set it apart from many contemporaries. Based in Monrovia, California, the company began its journey by enhancing an integral component of human life: vision. Through the skillful development and manufacture of implantable collamer lenses (ICLs), STAAR Surgical has thrived by providing solutions for those seeking alternatives to laser-based surgeries. Its ICL technology directly targets issues like myopia (nearsightedness) and astigmatism, offering patients a reversible, less invasive option than traditional corrective procedures. STAAR Surgical's business model hinges on a blend of specialized technology and strategic market penetration. The company primarily generates revenue by selling its suite of implantable lenses to healthcare providers and clinics worldwide, capitalizing on the rising trend of elective vision correction procedures. With its innovation-driven credo, STAAR continually invests in R&D to enhance its product offerings, ensuring it remains at the forefront of eye-care technology. By targeting emerging markets and expanding its global footprint, particularly in regions with growing demand for premium vision solutions, STAAR has positioned its unique value proposition to capitalize on both technological advancements and changing patient preferences. Through this deliberate strategy, STAAR not only bolsters its revenue streams but also fortifies its presence as a key player in the ophthalmic landscape.

STAA Intrinsic Value
26.42 USD
Undervaluation 13%
Intrinsic Value
Price

See Also

What is STAAR Surgical Co's Other Long-Term Assets?
Other Long-Term Assets
19.1m USD

Based on the financial report for Sep 27, 2024, STAAR Surgical Co's Other Long-Term Assets amounts to 19.1m USD.

What is STAAR Surgical Co's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
32%

Over the last year, the Other Long-Term Assets growth was 76%. The average annual Other Long-Term Assets growth rates for STAAR Surgical Co have been 65% over the past three years , 54% over the past five years , and 32% over the past ten years .

Back to Top